Jotic Ana, Milovanovic Jovica, Savic-Vujovic Katarina, Radin Zorana, Medic Branislava, Folic Miljan, Pavlovic Bojan, Vujovic Aleksandar, Dundjerovic Dusko
Clinic for Otorhinolaryngology and Maxillofacial Surgery, Clinical Center of Serbia, Belgrade, Serbia.
Medical Faculty, University of Belgrade, Belgrade, Serbia.
Dose Response. 2022 Jul 19;20(3):15593258221115537. doi: 10.1177/15593258221115537. eCollection 2022 Jul-Sep.
The aim of this study was to evaluate cell and biochemical biomarkers and establish their prognostic value in patients with advanced laryngeal cancer.
A prospective study included 52 patients with advanced laryngeal carcinoma surgically treated at the tertiary referral center. Tumor tissue was immunohistochemically stained for T-cell markers (CD4 and CD8), and levels of cytokines (IL-6 and IL-8) and C-reactive protein were analyzed from blood samples.
Overall 3-year survival (OS) of patients included in the study was 69.2% and the disease specific survival (DSS) 72.5%. Higher expression of CD4 and CD8 were significant prognostic factors with positive impact on both OS and DSS in univariate analysis, but not in multivariate analysis. Levels of IL-8 were a significant predictor of 3-year OS and DSS survival in patients with advanced laryngeal cancer but not levels of IL-6 and CRP values.
Though high expression of CD4 and CD8 were demonstrated in the tumor tissue, but their prognostic role was not established. Higher values of IL-8 proved to be significant negative predictor of DSS. This could further collaborate the inclusion of combination of biomarkers in assessment of favorable treatment choice in patients with advanced laryngeal carcinoma.
本研究旨在评估细胞和生化生物标志物，并确定它们在晚期喉癌患者中的预后价值。
一项前瞻性研究纳入了52例在三级转诊中心接受手术治疗的晚期喉癌患者。对肿瘤组织进行免疫组化染色，检测T细胞标志物（CD4和CD8），并分析血样中细胞因子（IL-6和IL-8）及C反应蛋白的水平。
本研究中患者的3年总生存率（OS）为69.2%，疾病特异性生存率（DSS）为72.5%。在单因素分析中，CD4和CD8的高表达是对OS和DSS均有积极影响的显著预后因素，但在多因素分析中并非如此。IL-8水平是晚期喉癌患者3年OS和DSS生存的显著预测指标，而IL-6水平和CRP值则不是。
虽然在肿瘤组织中证实了CD4和CD8的高表达，但其预后作用尚未确立。较高的IL-8值被证明是DSS的显著负性预测指标。这可能进一步支持将生物标志物组合纳入晚期喉癌患者有利治疗选择的评估中。
